High Court Won't Hear $70M Risperdal Verdict Challenge

By Matthew Santoni (May 17, 2021, 10:29 AM EDT) -- The U.S. Supreme Court won't review a $70 million verdict against a Johnson & Johnson unit for a Pennsylvania man who grew enlarged breasts from taking Risperdal, the court said Monday.

The Justices denied cert for J&J subsidiary Janssen Pharmaceuticals Inc.'s appeal of the 2016 verdict, in which a Philadelphia jury found the drugmaker liable for not adequately warning Andrew Yount and his family that the drug could cause gynecomastia, or male breast growth, when prescribed to adolescent boys.

Justice Samuel Alito did not participate in the decision, according to the unsigned order on the list of cases the court said...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!